Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

26.7%

4 terminated/withdrawn out of 15 trials

Success Rate

69.2%

-17.3% vs industry average

Late-Stage Pipeline

27%

4 trials in Phase 3/4

Results Transparency

11%

1 of 9 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

6(42.9%)

Phase 4

4(28.6%)

Phase 1

3(21.4%)

N/A

1(7.1%)

14Total

Phase 2(6)

Phase 4(4)

Phase 1(3)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT00406107Phase 4Completed

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

Role: collaborator

NCT01487044Unknown

A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema

Role: collaborator

NCT00295828Phase 1Completed

A Pilot Study for the Treatment of Iris Neovascularization With Macugen

Role: collaborator

NCT00346983Phase 1Terminated

Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics

Role: collaborator

NCT00358423Phase 1Terminated

The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema

Role: collaborator

NCT00088283Phase 2Completed

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

Role: lead

NCT00134667Phase 4Terminated

Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)

Role: lead

NCT00312351Phase 4Terminated

A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)

Role: lead

NCT00354445Phase 4Unknown

A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD

Role: lead

NCT00321997Phase 2Completed

A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.

Role: lead

NCT00215670Phase 2Completed

Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)

Role: lead

NCT00087763Phase 2Completed

Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)

Role: lead

NCT00040313Phase 2Completed

Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula

Role: lead

NCT00088192Not ApplicableCompleted

Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)

Role: lead

NCT00021736Phase 2Completed

Phase II/III Study of Anti-VEGF in Neovascular AMD

Role: lead

All 15 trials loaded